FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003279470> ?p ?o ?g. }

• W2003279470 endingPage "1673" @default.
• W2003279470 startingPage "1663" @default.
• W2003279470 abstract "The influence of cyclosporine A (CsA) treatment on the development of glomerulonephritis and glomerulosclerosis was investigated in chronic graft-versus-host disease (GvHD), a murine model for lupus nephritis. The renal disease is characterized by the formation of IgG-containing electron-dense deposits along the glomerular basement membrane (GBM) and in the mesangium, followed by the onset of proteinuria which starts, varying per individual mouse, about six weeks after the induction of the disease. Glomerular mRNA levels for matrix molecules were increased from week 4, preceding mesangial matrix expansion and GBM thickening which occurred from week 6. These initial events finally led to development of glomerulosclerosis, and end-stage renal failure. Groups of mice received three intraperitoneal (i.p.) injections per week with different doses of CsA, and treatment was started 2, 4, or 6 weeks after induction of the disease. Treatment with 10 or 50 mg CsA/kg/week did not influence the development of glomerulonephritis or glomerulosclerosis. Injection of 100 mg CsA/kg/week delayed the onset of proteinuria only when treatment was started in week 2. In week 6 some mice had already developed proteinuria whereas others had not. Treatment with 250 mg CsA/kg/week starting in week 6 abrogated glomerulonephritis and glomerulosclerosis only in those animals which were not yet proteinuric at that time. This, despite comparable increased autoantibody levels against DNA, GBM, and renal tubular epithelium (RTE) in both treated and untreated GvHD mice. Further increase in proteinuria and development of glomerulosclerosis could not be prevented if the mice already had developed proteinuria when CsA treatment was started. Dot blot analysis and in situ hybridization showed significantly decreased mRNA levels for alpha 1(I) and alpha 1(IV) collagen in kidneys of CsA-treated mice as compared to those of untreated mice 12 weeks after induction of the disease, if the highest dose of CsA was administered before the onset of proteinuria. No effect on these whole-kidney mRNA levels was observed in mice which had already developed proteinuria before CsA injections were started. Increased mRNA expression for matrix molecules in this group and in untreated GvHD mice was observed mainly in the interstitium. The kidneys of the treated GvHD mice and those of mice injected with 250 mg CsA/kg/week without induction of GvHD showed no morphological signs of CsA nephrotoxicity. We conclude that treatment with 250 mg CsA/kg/week prevents the development of glomerulonephritis and glomerulosclerosis in this model of lupus nephritis, if started before the onset of proteinuria.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2003279470 created "2016-06-24" @default.
• W2003279470 creator A5000085661 @default.
• W2003279470 creator A5004743827 @default.
• W2003279470 creator A5021917052 @default.
• W2003279470 creator A5029061765 @default.
• W2003279470 date "1994-12-01" @default.
• W2003279470 modified "2023-09-24" @default.
• W2003279470 title "Prevention of glomerulosclerosis by early cyclosporine treatment of experimental lupus nephritis" @default.
• W2003279470 cites W1966697776 @default.
• W2003279470 cites W1970799392 @default.
• W2003279470 cites W1981034641 @default.
• W2003279470 cites W1982882069 @default.
• W2003279470 cites W1984049148 @default.
• W2003279470 cites W1988200269 @default.
• W2003279470 cites W1992917873 @default.
• W2003279470 cites W1997411530 @default.
• W2003279470 cites W1999931966 @default.
• W2003279470 cites W2000469906 @default.
• W2003279470 cites W2004175072 @default.
• W2003279470 cites W2008701133 @default.
• W2003279470 cites W2014787563 @default.
• W2003279470 cites W2032574984 @default.
• W2003279470 cites W2037072024 @default.
• W2003279470 cites W2037925034 @default.
• W2003279470 cites W2038958380 @default.
• W2003279470 cites W2045031202 @default.
• W2003279470 cites W2048043023 @default.
• W2003279470 cites W2051016979 @default.
• W2003279470 cites W2052446249 @default.
• W2003279470 cites W2058980435 @default.
• W2003279470 cites W2060333964 @default.
• W2003279470 cites W2060695790 @default.
• W2003279470 cites W2067667982 @default.
• W2003279470 cites W2077214501 @default.
• W2003279470 cites W2079843436 @default.
• W2003279470 cites W2113581200 @default.
• W2003279470 cites W2319721505 @default.
• W2003279470 cites W2576734941 @default.
• W2003279470 doi "https://doi.org/10.1038/ki.1994.466" @default.
• W2003279470 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7700025" @default.
• W2003279470 hasPublicationYear "1994" @default.
• W2003279470 type Work @default.
• W2003279470 sameAs 2003279470 @default.
• W2003279470 citedByCount "21" @default.
• W2003279470 countsByYear W20032794702016 @default.
• W2003279470 crossrefType "journal-article" @default.
• W2003279470 hasAuthorship W2003279470A5000085661 @default.
• W2003279470 hasAuthorship W2003279470A5004743827 @default.
• W2003279470 hasAuthorship W2003279470A5021917052 @default.
• W2003279470 hasAuthorship W2003279470A5029061765 @default.
• W2003279470 hasBestOaLocation W20032794701 @default.
• W2003279470 hasConcept C126322002 @default.
• W2003279470 hasConcept C134018914 @default.
• W2003279470 hasConcept C203014093 @default.
• W2003279470 hasConcept C2776115139 @default.
• W2003279470 hasConcept C2777058396 @default.
• W2003279470 hasConcept C2777390665 @default.
• W2003279470 hasConcept C2778415529 @default.
• W2003279470 hasConcept C2778653478 @default.
• W2003279470 hasConcept C2779134260 @default.
• W2003279470 hasConcept C2779561371 @default.
• W2003279470 hasConcept C2779912601 @default.
• W2003279470 hasConcept C2780091579 @default.
• W2003279470 hasConcept C2780368995 @default.
• W2003279470 hasConcept C2780688133 @default.
• W2003279470 hasConcept C71924100 @default.
• W2003279470 hasConceptScore W2003279470C126322002 @default.
• W2003279470 hasConceptScore W2003279470C134018914 @default.
• W2003279470 hasConceptScore W2003279470C203014093 @default.
• W2003279470 hasConceptScore W2003279470C2776115139 @default.
• W2003279470 hasConceptScore W2003279470C2777058396 @default.
• W2003279470 hasConceptScore W2003279470C2777390665 @default.
• W2003279470 hasConceptScore W2003279470C2778415529 @default.
• W2003279470 hasConceptScore W2003279470C2778653478 @default.
• W2003279470 hasConceptScore W2003279470C2779134260 @default.
• W2003279470 hasConceptScore W2003279470C2779561371 @default.
• W2003279470 hasConceptScore W2003279470C2779912601 @default.
• W2003279470 hasConceptScore W2003279470C2780091579 @default.
• W2003279470 hasConceptScore W2003279470C2780368995 @default.
• W2003279470 hasConceptScore W2003279470C2780688133 @default.
• W2003279470 hasConceptScore W2003279470C71924100 @default.
• W2003279470 hasIssue "6" @default.
• W2003279470 hasLocation W20032794701 @default.
• W2003279470 hasLocation W20032794702 @default.
• W2003279470 hasOpenAccess W2003279470 @default.
• W2003279470 hasPrimaryLocation W20032794701 @default.
• W2003279470 hasRelatedWork W1964620820 @default.
• W2003279470 hasRelatedWork W1985875331 @default.
• W2003279470 hasRelatedWork W2003279470 @default.
• W2003279470 hasRelatedWork W2351688851 @default.
• W2003279470 hasRelatedWork W2372373847 @default.
• W2003279470 hasRelatedWork W2404523890 @default.
• W2003279470 hasRelatedWork W2410935381 @default.
• W2003279470 hasRelatedWork W2413373368 @default.
• W2003279470 hasRelatedWork W2494278441 @default.
• W2003279470 hasRelatedWork W2762701397 @default.
• W2003279470 hasVolume "46" @default.

• next